US FDA gives green light to UCB’s drug for rare childhood epilepsy
The FDA also granted paediatric exclusivity to the oral solution, branded Fintepla.
Belgian biopharma company UCB announced today that its drug for the treatment of seizures caused by Lennox-Gastaut syndrome, a rare form of childhood-onset epilepsy, has been approved by the US Food and Drug Administration.
The oral solution Fintepla (fenfluramine) was already approved in the US and EU for the treatment of seizures associated with Dravet syndrome in patients two and older. It will be available for treatment of Lennox-Gastaut syndrome (LGS) in the US through a restricted distribution programme.
LGS is a severe form of childhood epilepsy that is characterised by multiple types of seizures, cognitive dysfunction, impaired motor function, and in some cases sudden unexpected death in epilepsy (SUDEP). UCB's Zogenix unit estimates that about 30,000 to 50,000 people have LGS in the United States.
The FDA approval was supported by safety and efficacy data from a global, randomised, placebo-controlled Phase 3 clinical trial in 263 patients with LGS.
Fintepla’s approval comes just a few weeks after UCB closed its acquisition of biopharmaceutical firm Zogenix, who developed the drug, in a deal valued at up to $1.9 billion. Fintepla is also being targeted as a treatment for a genetic epilepsy called CDKL5 deficiency disorder in a Phase 3 trial. Before the acquisition, Zogenix stated that the drug could reach $1 billion in peak sales.
Fintepla adjusts a receptor called Sigma 1, which controls how brain cells communicate with each other. It comes with a boxed warning for heart and lung conditions such as valvular heart disease and pulmonary arterial hypertension.
UCB’s Fintepla will now be in direct competition with Jazz Pharmaceuticals’ cannabis-based Epidiolex, which was approved to treat seizures related to Dravet Syndrome and LGS in 2018. Other drugs with a similar offering to Fintepla include Takeda Pharmaceutical's soticlestat and Eisai’s lorcaserin and Fycompa.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance